Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Prev ABR (Clostridium Difficile Infectious Disease Program)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Portfolio of biologic compounds in Maryland, United States. The portfolio comprises of a series of beta-lactamase compounds (P1A, P2A and P3A) to prevent and treat multidrug-resistant infectious diseases.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Commercial Services
Other Industries
Buildings and Property
Pharmaceuticals
Primary Office
  • 4800 Hampden Lane
  • Suite 200
  • Bethesda, MD 20814
  • United States

Prev ABR (Clostridium Difficile Infectious Disease Program) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Prev ABR (Clostridium Difficile Infectious Disease Program)‘s full profile, request access.

Request full access to PitchBook

Prev ABR (Clostridium Difficile Infectious Disease Program) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Prev ABR (Clostridium Difficile Infectious Disease Program)‘s full profile, request access.

Request full access to PitchBook